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ABSTRACT
Introduction Progress in degenerative cervical
myelopathy (DCM) is hindered by inconsistent
measurement and reporting. This impedes data
aggregation and outcome comparison across studies.
This limitation can be reversed by developing a core
measurement set (CMS) for DCM research. Previously,
the AO Spine Research Objectives and Common Data
Elements for DCM (AO Spine RECODE-DCM) defined ‘what’
should be measured in DCM: the next step of this initiative
is to determine ‘how’ to measure these features. This
protocol outlines the steps necessary for the development
of a CMS for DCM research and audit.
Methods and analysis The CMS will be developed in
accordance with the guidance developed by the Core
Outcome Measures in Effectiveness Trials and the
Consensus-based Standards for the selection of health
Measurement Instruments. The process involves five
phases. In phase 1, the steering committee agreed on
the constructs to be measured by sourcing consensus
definitions from patients, professionals and the literature.
In phases 2 and 3, systematic reviews were conducted
to identify tools for each construct and aggregate
their evidence. Constructs with and without tools were
identified, and scoping reviews were conducted for
constructs without tools. Evidence on measurement
properties, as well as on timing of assessments, are
currently being aggregated. These will be presented
in phase 4: a consensus meeting where a multi-
disciplinary panel of experts will select the instruments
that will form the CMS. Following selection, guidance
on the implementation of the CMS will be developed
and disseminated (phase 5). A preliminary CMS review
scheduled at 4 years from release.
Ethics and dissemination Ethical approval was obtained
from the University of Cambridge (HBREC2019.14).
Dissemination strategies will include peer-reviewed
scientific publications; conference presentations; podcasts;
the identification of AO Spine RECODE-DCM ambassadors;

Strengths and limitations of this study
⇒ The core measurement set (CMS) will be estab-

lished using a robust, global and multi-stakeholder
consensus process, with broad representation of
healthcare professionals and individuals living with
the disease.
⇒ The CMS will only focus on measurement instruments currently in use and exclude instruments
under development, translational research, or in languages other than English.
⇒ Where there are gaps in degenerative cervical myelopathy outcome measurement, systematic and
targeted scoping reviews will be performed to identify instruments used in related populations, which
are likely but not guaranteed to measure equivalent
outcome constructs.
⇒ The CMS will be selected using modified nominal
group techniques that have been effectively used
during previous consensus processes.

and engagement with relevant journals, funders and the
DCM community.

INTRODUCTION
Background
Degenerative cervical myelopathy (DCM)
is a common and often disabling disease.1
Estimated to affect as many as one in fifty
adults,1 it develops due to degenerative and/
or congenital changes in the cervical spine
leading to mechanical stress and a progressive spinal cord injury.2–4 This disease can
lead to a wide variety of symptoms, affecting
the whole body.5 These symptoms commonly
include gait dysfunction, imbalance and falls,
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loss of strength and manual dexterity, and pain. Despite
current best practice,6 a minority of patients will make a
full recovery and DCM is often associated with lifelong
disability, impaired quality of life and significant costs to
both the individual and to society.7 8
While progress has been and is being made,6 9 there
remain significant knowledge gaps. For people affected
by DCM, solutions to these challenges cannot come soon
enough.10 AO Spine Research Objectives and Common
Data Elements for Degenerative Cervical Myelopathy
(AO Spine RECODE-DCM; www.aospine.org/recode) is
an international, multi-
stakeholder initiative originally
formed to create a ‘research toolkit’ that could help
accelerate knowledge discovery and improve outcomes in
DCM.11 12 This project aimed to unify terminology, and
develop minimum standards for measurement and data
reporting,12–14 in order to enable data aggregation and
implementation of management recommendations.15–17
The value of addressing these inefficiencies is likely
magnified for DCM, as the research community is relatively small, fragmented and has not received commensurate attention or funding.18 19 This is magnified by the use
of 14 different names around the world, with common
alternatives including cervical spondylotic myelopathy,
cervical myelopathy and cervical stenosis.20
So far, AO Spine RECODE-DCM has established the
top research priorities and agreed on a single definition
and index term.4 8 21–32 It has also agreed on ‘what’ should
be measured in DCM research: that is, a minimum data
set, which is comprised core data elements (CDE) and
a core outcome set (COS). The COS is composed of
six domains: neuromuscular function, life impact, pain,
radiology, economic impact and adverse events. Each
domain contains a list of more specific outcomes that
should be measured. While adherence to this minimum
dataset should ensure a more comprehensive assessment
of DCM, to ensure data is reported in a consistent manner,
best suited for between study comparison and evidence
synthesis, this standardisation should also extend to ‘how’
the dataset should be measured and reported. This additional phase is referred to as the development of a core
measurement set (CMS) (table 1).33–35
A CMS is a set of agreed on tools that are used to measure
the CDE and COS.36 A CMS is needed to improve the
consistency of data measurement and reporting across
DCM and will ultimately accelerate changes that will
improve outcomes for this population.12 This protocol
defines how AO Spine RECODE-DCM will establish a
CMS for DCM.

Table 1 Research Objectives and Common Data Elements
for DCM definitions and terminology
Acronym

Definition

CDE
ClinROM

Core data elements
Clinician Reported Outcome Measure

CMS

Core measurement set

COMET

Core Outcome Measures in Effectiveness
Trials

COS

Core outcome set

COSMIN

Consensus-based Standards for the
selection of health Measurement
Instruments

DCM

Degenerative cervical myelopathy

IMMPACT

Initiative on methods, measurement and
pain assessment in clinical trials

PROM

Patient-reported outcome measure

SC

Steering committee

Minimum data set terminology
The minimum data set refers to the COS and CDE together.
At a collective level we refer to each individual feature as
elements. When referring to an element of the COS, we use
the term outcome. When referring to an element of the CDE,
we use data element.
The COS is composed of six domains, each of which
contains a number of specific outcomes:
Neuromuscular
Radiology
function
Economic impact
Life impact
Adverse events
Pain
*This field is rich with acronyms and terms, often bearing close
resemblance in sentiment but with different precise meaning. This
table lists the acronyms and terms used in this protocol.

METHODS AND ANALYSIS
Overview and scope
The CMS will continue to be managed within the framework of AO Spine RECODE-
DCM.11 Ethical approval
for this project was obtained from the University of
Cambridge (ethical approval number: HBREC2019.14).
A multi-disciplinary, global steering committee (SC) was

formed for the oversight of the project (www.aospine.
org/recode). In addition to interim correspondence, the
committee meets at least two times a year. For a meeting to
be considered quorate, it must include at least two people
with lived experience and four healthcare professionals.
When a steering group member is unable to attend,
decisions made at quorate meetings are respected. Day-
to-day administration is provided by a multi-stakeholder
management group.
As outlined earlier, the standardisation of data measurement and reporting is an immediate priority for DCM.
However, the research priority-
setting process further
recognised a need to develop new measurement instruments for DCM.27 Acknowledging that such development demands a significant period of time and financial
support, it was decided that the initial CMS should focus
on selecting the most relevant—but existing—instruments, as opposed to developing new tools or selecting
those early in development. The added benefit would be
to enable comparisons with historic data while simplifying
the implementation of DCM’s first minimum dataset.
This rationale is expanded in the discussion.
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Figure 1

Overview of the core measurement set (CMS) process.

The development of the CMS is based on relevant guidance, including that developed by the Core Outcome
Measures in Effectiveness Trials and the Consensus-
based Standards for the selection of health Measurement
Instruments (COSMIN).36–44 Notably, no more than one
measurement tool will be selected per core outcome.36
The developmental process will be conducted in five
phases (figure 1):
1. Phase 1: to agree on the measurement construct and
preferred measurement approach.
2. Phase 2: to identify measurement tools and evaluate
their evidence base.
3. Phase 3: to aggregate the evidence on timing of assessment.
4. Phase 4: to select the most appropriate instruments
through multi-stakeholder consensus and provide reporting guidance.

5. Phase 5: to implement the CMS
The CMS will cover each element contained within
the CDE but each domain of the COS (the minimum
dataset). For phases 1 and 2, preparatory scoping work
will focus on the specific outcomes but during phase 4
(Consensus), this detail will be used to inform a representative measurement instrument or instruments for
the domain as a whole. Elements in the CDE which
are descriptive (eg, individual’s age or sex) and do not
require measurement per se, will only feature in phases
3 and 4. These elements will be identified and agreed
during phase 1.
Information on the status of each phase is shown
in table 2. Where a phase has not yet been completed,
information on the planned timeline for completion is
described as of the time of peer-review.

Table 2 Status of the CMS process
Phase

Status

Description

1
2

Complete
In progress

 
Systematic review of the quality of existing measurement instruments published45
Gap analysis completed (table 3)
Targeted scoping reviews in progress (ETC April 2022)

3

In progress

ETC May 2022

4
5

Scheduled
In planning

Consensus meeting is scheduled for 1 June 2022
Strategy to be refined with finalised CMS

CMS, core measurement set ; ETC, estimated time of completion.
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Patient and public involvement
This project forms part of a larger, international multi-
stakeholder co-
production initiative called AO Spine
DCM, which aims to develop a framework
RECODE-
to accelerate knowledge discovery that can improve
outcomes in DCM. Patients and the public were therefore
involved in its overall design, conduct, management and
dissemination, and are recognised among the authors of
this article (for further information, refer to www.aospine.
org/recode).
Phase 1: forming measurement constructs and establishing
the preferred measurement approach
During the formation of the CDE and COS, each
element was summarised with a lay description. While
this provided an explanation as to how the term was originally proposed, for example, based on content from
interviews,5 10 these descriptions were not intended as
construct definitions. Further, as some outcomes were
merged and/or renamed during the process, they lacked
a unifying explanatory statement.
Consequently, the first step of this CMS is to agree on
the specific construct to be measured.36–44 These will
be expressed by forming a definition for each element.
Draft definitions will be generated from original source
documents including published literature or interviews
with patients and professionals. This will be undertaken
by the management group. These provisional definitions
will then be reviewed by the SC and iterated as indicated.
Each definition must reach >70% approval at a quorate
meeting to be considered final.
For elements requiring measurement, the SC will also
define through agreement, whether it should be ideally
measured by people with DCM (ie, a patient-reported
outcome measure, or PROM), a healthcare professional
(ie, a clinician-reported outcome measure, or ClinROM),
or both. These decisions will not necessarily be considered binding for the final CMS owing to the uncertainty
at this stage around the availability and quality of candidate measures. The decision instead will be used during
phase 4, to help inform the selection of instruments for
the CMS.

Systematic review of existing measurement instruments
A systematic review was used to evaluate the quality of
a predefined list of existing measurement instruments,
identified from three previous scoping reviews.13 45–47 The
term ‘measurement instrument’ was used to refer to how
the element was being measured (ie, the instrument used
to assess the outcome) and could refer to a single question, a questionnaire, or other instruments,48 49 including
PROMs and ClinROMs.
The search was performed in EMBASE and MEDLINE
from inception until 4 August 2020 to identify original
research assessing the measurement properties of instruments used in clinical research of DCM. The search string
was built using the relevant DCM search filter50 51 and the
COSMIN filter for studies evaluating measurement properties.52 Abstracts were screened by four reviewers against
a set of predefined criteria (online supplemental table 1).
Only primary clinical research studies evaluating one or
more measurement properties were included.
All data were collected, processed and analysed in
accordance with the COSMIN manual for systematic
reviews of PROMs. This involved collecting results across
10 measurement properties: content validity, structural
cultural validity/
validity, internal consistency, cross-
measurement invariance, reliability, measurement error,
criterion validity, hypotheses testing for construct validity,
responsiveness and clinically important differences.
Results were rated as ‘sufficient’, ‘indeterminate’ or
‘insufficient’ and overall methodological quality scores
were scored as ‘very good’, ‘adequate’, ‘doubtful’, ‘inadequate’ or ‘not applicable’, as described in the manual.
Results were then qualitatively summarised and an overall
rating of the quality of the studies was made using a modified Grading of Recommendations Assessment, Development and Evaluation approach, as described in the
manual. Recommendations were formulated based on all
evidence, a list of interpretable instruments was collated
and findings were subsequently reported as a narrative
synthesis.53

Phase 2: identifying potential instruments and evaluating their
measurement properties
Phase 2 will be conducted in three stages: (2.1) a systematic review to assess the quality of existing measurement instruments used in DCM; (2.2) a gap analysis of
elements, to identify those for which a measurement
instrument of sufficient quality within DCM does not
exist and (2.3) targeted scoping reviews of these gap
elements, to identify potentially relevant instruments
used outside of DCM.
Phases 2.1 and 2.2 have been completed. Phase 2.1
has been published separately45; thus, only a summary
is provided here. Phase 2.2 and its results are included
here.

Gap analysis
While the review identified clinically interpretable instruments that were common to DCM research and could be
used to measure outcomes in the COS, there were: (a)
several elements for which no existing instrument was
appropriate and (b) several instruments for which the
evidence base was deemed inadequate.36
To identify candidate instruments for these gaps, we
looked for appropriate instruments outside of the field
of DCM. Before conducting scoping reviews for each gap
de novo, a pragmatic MEDLINE search was performed
to assert if such reviews already existed. Outcomes
within the domain of pain were excluded as it was felt
the resources and recommendations aggregated by the
Initiative on Methods, Measurement and Pain Assessment in Clinical Trials were sufficient.54 Search strings
were formed, comprising the core outcome, synonyms of
‘psychometric’ and ‘Neuroscience’,50 52 and were limited
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Table 3 Gap analysis
Domain

Outcome

Interpretable measurement instrument(s) identified

Adverse events

Death
Surgical adverse events

0 (N=55)

Economic impact

Cost of care
Employment status

Life impact

0 (N=5)

Dependence
Falls

0 (N=173)

Fatigue

1 (N=207)

Mental health
Mobility
Neuromuscular function

Arm strength
Balance
Bladder function
Faecal incontinence

0 (N=308)

Finger/hand dexterity
Finger strength
Grip strength
Leg strength
Muscle tone and spasticity

0 (N=39)

Neck mobility
Sensation
Pain

Location
Intensity
Pain control
Perception

Radiology

Adjacent segment degeneration

0 (N=69)

Cervical spine alignment

0 (N=24)

Cord compression
Cord signal change

0 (N=69)
0 (N=24)

Elements with at least one interpretable instrument (see phase 2.1) are shaded green and will be published separately. Targeted searches
of MEDLINE were performed for the remaining elements (ie, ‘gaps’, unshaded, see phase 2.2). For gaps within the domain of pain (shaded
blue), the resources aggregated by Initiative on Methods, Measurement and Pain Assessment in Clinical Trials were deemed sufficient.79 The
number of articles (N) screened is indicated for each gap. Notably, only one suitable resource was identified for ‘fatigue’.55

to the last 5 years to ensure relevance. The search was
restricted to Neuroscience as it was anticipated this would
most likely identify instruments with appropriate content
validity. Abstracts were screened by one reviewer against
the same criteria from the review (online supplemental
table 1). Results from this gap analysis are aggregated in
table 3. Notably, no systematic reviews were identified, but
a published protocol with respect to fatigue was, and the
study results obtained via personal communication.55
Targeted scoping reviews
For those remaining outcomes without potential instruments, focused scoping reviews will be conducted. These
reviews will be conducted in two stages and will aim to:
(a) identify instruments used in a related target population (to increase the likelihood of content validity) and
Davies BM, et al. BMJ Open 2022;12:e060436. doi:10.1136/bmjopen-2021-060436

(b) evaluate the methodological quality of those identified instruments. Recognising the intensive undertaking of reviewing the quality of instruments using the
COSMIN methodology, in order to ensure this undertaking is manageable and likely to yield relevant results,
it will be conducted in the following pragmatic fashion
(figure 2):
Stage 1
1.1 Identify tools outside DCM for domains in phase
2.2.
► 1.2 Screen tools from stage 1.1 according to intended
format, that is, ClinROM or PROM.
►

Stage 2
2.1 Evaluate content validity of PROMs from stage 1.

►
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Figure 2 Decision tree schematic illustrating the targeted scoping review process. (A and B) Stage 1: selection of databases
for identification of tools outside degenerative cervical myelopathy (DCM) (A) and screening of tools outside DCM (B). (C) Stage
2: evaluation of measurement properties. COSMIN, Consensus-based Standards for the selection of health Measurement
Instruments; EULAR OML, EULAR Outcomes Measures Library.

2.2 Evaluate content validity of ClinROMs from stage
1.
► 2.3 Select two PROMs and ClinROMs from stages 2.1
and 2.2.
► 2.4 Evaluate measurement properties of tools selected
in stage 2.3.
► 2.5 Share list of tools with psychometric evaluations
ahead of consensus meeting.
To identify instruments, each ‘gap’ outcome will be
queried first on the COSMIN database of systematic
reviews of outcome measurement instruments (https://
database.cosmin.nl/) (figure 2A). As a scoping exercise,
each search will focus on reviews in order to develop a
list of measurement instruments. Preferably, systematic reviews identifying instruments and evaluating their
methodological quality will be included (figure 2B).
Where these are not available, systematic reviews identifying instruments without methodological evaluations will
be favoured, followed by reviews referred from SC advice
and, ultimately, primary literature.
Searches will be conducted in disease populations
related to DCM in order to increase the likelihood of
content validity. For example, ‘faecal incontinence’,
could be a symptom of many diseases. However, since
this symptom is also measured in other spinal disorders
with neurological injury (eg, traumatic spinal cord injury
and cauda-
equina syndrome), these disorders would
be considered appropriate populations. These will be
defined with input from stakeholders a priori.
As in phase 1, instruments will be categorised as
PROMs or ClinROMs.56 Only instruments whose category matches the intended outcome category, as defined
in phase 1, will be included. Namely, if ‘faecal incontinence’ was defined as a patient-reported outcome during
phase 1, then only PROMs of ‘faecal incontinence’ will be
included, and ClinROMs will be excluded.

The above steps will be performed for each ‘gap’
outcome in table 3 in order to identify instruments used
in related target populations. If no such instruments are
found through the COSMIN database, the same steps
will be performed on the EULAR Outcomes Measures
Library (OML, https://oml.eular.org/) (figure 2A). If no
such instruments are found through the EULAR OML,
the same search will be performed, as a last resort, on
the HealthMeasures Database (https://www.healthmeasures.net/), failing which, the search will be performed
on PubMed using the COSMIN filter.52 These databases
were selected based on their scope.
To evaluate the methodological quality of the identified
instruments, the same COSMIN process as in phase 2.145
will be used. Recognising that evaluating an uncapped
number of instruments with the COSMIN manual can
quickly become unrealistic, we will limit the number
of instruments for COSMIN review to two per ‘gap’
outcome. Should there be more than two PROMs or ClinROMs per ‘gap’ outcome, a content validity survey will be
conducted on at least five people with lived experience
or clinicians (as applicable) to rank the identified instruments (figure 2C). The two highest ranking instruments
will be selected for COSMIN review and their psychometric properties will be evaluated as in phase 2.1.45
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►

Phase 3: evidence on timing of assessment
The timing of the assessment is an additional source
of variation with respect to aggregating outcomes. For
studies considering non-operative management due to
the current uncertainty around the natural history of
DCM (recognised as a critical research priority)57 this
will not be possible. However, for DCM managed operatively, the recovery profile is more stereotyped and felt
amenable to standardisation measurement time points.
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To help inform this recommendation, an evaluation of the AO Spine Cervical Spondylotic Myelopathy
(CSM) North America and International datasets will
be conducted.58 59 These are two high-quality observational studies of patients undergoing surgery for DCM,
followed up at 3, 6, 12 and 24 months after surgery. These
incorporate the most frequently used follow-
up timepoints from DCM research.13 Recovery trajectories will be
modelled over time, including the proportion of patients
achieving maximal recovery at each follow-up point and
the percentage change from last follow-up. The significant of contextual factors that may influence this (eg, age
or comorbidities) will also be explored. These findings
will be shared during phase 4.
Phase 4: consensus recommendations
Formation of an expert consensus panel
A multi-disciplinary panel of experts will be formed to
finalise the CMS through consensus. These experts will
be identified using purposive sampling to include people
with lived experience; professionals from key clinical
disciplines commonly involved in DCM care (ie, spinal
surgery, neurology, rehabilitation medicine, physiotherapy and primary care)12 60; professionals with clinical
trials experience, particularly with respect to measuring
each of the six domains (ie, adverse events, economic
impact, life impact, neuromuscular function, pain and
radiology); and professionals with experience in trial
statistics. A target sample size of 12 individuals will be
sought. At least half of all participants will be external to
the SC; at least one in six participants will have lived experience; and no more than half of all participants will be
spinal surgeons. It is also intended to have a 1:1 ratio of
women to men. All panellists must declare any conflicts of
interest, and be approved by the SC.
Pre-meeting short-listing
Panellists will be provided with a summary containing the
identified measurement instruments considered of sufficient quality for each element, including their evidence
base, and the original steering committee decision
concerning the preferred reporting method (ie, PROM
or ClinROM). Each panellist will be asked to submit
two preferred measurement instruments in advance of
the meeting. These may include the instruments identified and evaluated during phase 2 or up to two instruments from outside this list. To justify the suggestion of
instruments from outside the provided list, panellists will
be asked to cite one primary article per psychometric
domain (ie, one for validity, one for reliability and one
for responsiveness). This literature will be evaluated
using the same COSMIN methodology from phases 2.1
and 2.3, to ensure that all instruments presented at the
face-to-face consensus meeting are accompanied with a
COSMIN rating and comparable.

instruments, (b) to define how they should be reported
and (c) to outline when they should be reported in surgically treated DCM cohorts. The management group will
prepare documentation for each domain, comprising
those instruments shortlisted by the panel during phase
4.2 together with their evidence. Each domain will be
discussed in turn with a majority decision considered
consensus agreement. Where applicable, this will also
continue for each element of the CDE. The consensus
meeting will be overseen by an independent facilitator
and follow a modified nominal group technique. Moderated discussion and re-voting will be undertaken as necessary until consensus is achieved for all components of
the COS and CDE. Consensus will be defined as >70%
agreement.
Phase 5: implementation
The dissemination of the CMS will be incorporated into
the active knowledge translation proposal for the entire
AO Spine RECODE-DCM initiative. This includes scientific publication; conference presentations; podcasts;
identifying AO Spine RECODE-DCM ambassadors; and
engaging with relevant journals and funders. This process
will be subject to periodic review to ensure strategies are
effective and adaptive.
This will include a survey of the RECODE-DCM community, designed to share the CMS and ascertain barriers to
implementation. This information will be used to inform
overall strategy.
The AO Spinal Cord Injury Knowledge Forum, an international and multidisciplinary group of professionals
working in this field, will review the relevance of the CMS
at 4 years from release, to consider whether an update is
required.

ETHICS AND DISSEMINATION
Ethical approval was obtained from the University of
Cambridge (HBREC2019.14). Participant consent will
be sought for the consensus meeting. Members of the
SC have already consented to participate in this study.
Dissemination strategies for this project will include
scientific publication, presentation and communication,
and are described in more detail in phase 5.

DISCUSSION
This protocol outlines the process for developing a CMS
for DCM, based on the CDE and COS already defined
by AO Spine RECODE-
DCM. While some pragmatic
steps have been taken, this process remains faithful to
consensus methodology and CMS precedent36–44 48 and,
ultimately, remains robust.

Face-to-face consensus meeting
A consensus meeting of the panel will then be convened.
The aims will be: (a) to select the preferred measurement

CMS will focus on measurement instruments currently in
usage
From the outset, it was decided that the CMS would principally focus on existing instruments currently in use.
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Although the development of better assessment instruments is a top 10 research priority,27 the strategy to use
existing instruments was preferred for several reasons.
First, the aim of this project was to develop a CMS that
could be immediately implemented in clinical practice and
research studies. The development of new tools remains
a work in progress, including microstructural MRI, gait
laboratory analysis and clinical assessments.27 30 61 While
it seems inevitable that these measurement instruments
will change DCM assessment, there remain important
methodological uncertainties, practical challenges and
technological requirements that pose potential barriers
to adoption.
Widespread adoption is necessary for a minimum data
set to improve research efficiency. Unless individual DCM
researchers have unified data collection, the comparison
of findings across studies will remain limited.62 Changing
practice, however, is challenging, particularly when a
concept is unfamiliar or questioned.63–65 It is therefore
important to recognise that CMSs can be updated66 and
that individual studies can incorporate additional instruments at their discretion. Furthermore, the inclusion of
emerging technology should only be included in future
CMS iterations when their selection is undisputable.
For DCM, an equally important but more achievable
priority is to ensure that the intended breadth of outcomes
is being measured. As highlighted in phase 2.2, previous
studies may have underrepresented the disease.13 18 This
holds significant implications for interpreting the literature. A recent example is the results of the CSM-Protect
study, a randomised controlled trial comparing riluzole as an adjuvant to surgery to surgery alone.67 While
there were no differences between treatment groups
with respect to the primary endpoint (ie, neuromuscular
function), there were indications of meaningful benefit
among secondary outcomes (eg, complications such as
C5 Nerve Palsy, and pain).
As a nascent research field with a paucity of high-quality
prospective studies,6 9 ensuring that current research is
comparable to these benchmarks will be important for
their generalisation and implementation in the short
term.17 This will require existing measurement instruments to be represented.

developing a global multi-stakeholder community focused
on DCM.32 Arguably, ‘how’ to measure these outcomes
will require further focused perspectives on clinical
assessment and trials. When conducting our international
Delphi processes, engaging under-
represented stakeholders was challenging.12 22 74 At the outset, we aimed
to capture perspectives of people with lived experiences,
surgeons and other healthcare professionals in a 2:1:1
ratio.12 However, this could not be achieved, and engaging
spinal surgeons—who most frequently treat, research,
and specialise in DCM—was much easier.22 Given that the
CDE and COS have been defined, and that the decision
on how to measure them is likely to benefit from specific
expertise, a purposively selected group using a modified
nominal group technique was favoured for the CMS. It is
also hypothesised that the step of sharing the results of
the CMS with the wider DCM research community will
facilitate dissemination and improve face validity.

CMS will be selected using modified nominal group
techniques
Several methods exist to achieve meaningful consensus.68 69
Ultimately, these methods aim to ensure that all relevant
perspectives are captured and appropriately represented
in the decisions taken.70 Consensus processes are increasingly approached by combining literature evidence,
serial surveys and a final consensus meeting—a modified
Delphi.68 71 72 This approach was effectively used during
our previous three consensus processes (ie, for the index
term, CDE, and COS).
The diverse perspectives from different stakeholder
groups was imperative in determining ‘what’ to measure,
identifying previously unprioritised outcomes73 and

Limitations
Despite its conscientious design, this CMS process has
limitations. As in Yanez Touzet et al,45 in searching for
existing instruments, we have neither identified nor
assessed tools under development, or those currently
being translated into clinical or research settings, or
those published in languages other than English. Further,
to ensure that the identification and evaluation of candidate tools in use outside of DCM is manageable, pragmatic steps have been taken. While this risks missing
relevant tools, we suspect this is very unlikely to limit the
CMS. First, the shortlisting takes a systematic and structured approach, adapted from the prioritisation of databases and standards in the COSMIN website and manual
(respectively).37–39 75 This was supplemented by the
perspectives of the SC, which includes significant DCM
research experience and remains open to suggestions
from those attending the consensus meeting.
Notably, in the gap analysis, only one suitable resource
was identified out of 973 candidates (table 3). This paucity
of high-quality evidence is not surprising given our prior
experience with the COSMIN guidelines.45 The COSMIN
standards set a high bar for evaluating psychometric
assessments. For example, studies on content validity
cannot score higher than ‘inadequate’ without focus
group/interview recordings or verbatim transcriptions—
and, in our experience, most of these studies rely on
survey-based methods. These standards have been previously conceived as both strengths, and limitations, of the
COSMIN methodology.76–78 That only one outcome out
of 28 had one suitable resource was noteworthy at the gap
analysis stage but, when interpreted within the context of
the psychometric rigour (or stringency) of the guidelines,
it is neither surprising nor worrying due to our intent to
include the highest possible quality of instruments in this
CMS.55
Finally, in resorting to shortlisted instruments used
in populations other than DCM, we have introduced
the possibility for invalid instruments to be selected. To
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minimise this limitation, we stipulated that the constructs
being measured in these populations must be, in all likelihood, equivalent, that is, there is content validity. This
was desirable due to the number of gaps in phase 2.2 and
feasible due to the COSMIN recommendations.37–39 As in
shortlisting, the option for experts to suggest other instruments prior to the consensus meeting should provide an
opportunity to resolve this limitation as much as possible.
Alternatively, the expert discussions, voting and re-voting
involved in the modified nominal technique should
address these concerns explicitly.
We anticipate that the formation of the first CMS for
DCM will greatly facilitate knowledge generation and
knowledge translation in DCM by enabling clinicians and
researchers to ‘speak a common language’ with regard
to outcomes instruments. We hope that this set, which
will focus on instruments in current use, will facilitate the
standardised and comprehensive measurement of DCM
and inspire a framework for the development and adoption of improved measures.
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